WO1994018307A1 - Cell induction device - Google Patents
Cell induction device Download PDFInfo
- Publication number
- WO1994018307A1 WO1994018307A1 PCT/US1994/001561 US9401561W WO9418307A1 WO 1994018307 A1 WO1994018307 A1 WO 1994018307A1 US 9401561 W US9401561 W US 9401561W WO 9418307 A1 WO9418307 A1 WO 9418307A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- laminate
- chamber
- εaid
- cells
- matrix material
- Prior art date
Links
- 230000006698 induction Effects 0.000 title claims abstract description 28
- 239000000463 material Substances 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 30
- 230000004069 differentiation Effects 0.000 claims abstract description 25
- 230000001939 inductive effect Effects 0.000 claims abstract description 23
- 238000004891 communication Methods 0.000 claims abstract description 5
- 230000024245 cell differentiation Effects 0.000 claims abstract description 4
- 239000000758 substrate Substances 0.000 claims description 75
- 239000011159 matrix material Substances 0.000 claims description 71
- 230000002093 peripheral effect Effects 0.000 claims description 53
- 210000000988 bone and bone Anatomy 0.000 claims description 33
- 102000008186 Collagen Human genes 0.000 claims description 31
- 108010035532 Collagen Proteins 0.000 claims description 31
- 229920001436 collagen Polymers 0.000 claims description 31
- 125000006850 spacer group Chemical group 0.000 claims description 27
- 230000012010 growth Effects 0.000 claims description 26
- 210000001519 tissue Anatomy 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 12
- 101710172711 Structural protein Proteins 0.000 claims description 11
- 238000012856 packing Methods 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 6
- 229920000288 Keratan sulfate Polymers 0.000 claims description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 229920002971 Heparan sulfate Polymers 0.000 claims description 3
- 230000010261 cell growth Effects 0.000 claims description 3
- 239000012530 fluid Substances 0.000 claims description 3
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 claims description 3
- 230000002188 osteogenic effect Effects 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000000921 morphogenic effect Effects 0.000 claims description 2
- 230000000284 resting effect Effects 0.000 claims description 2
- 238000000151 deposition Methods 0.000 claims 2
- 229920002567 Chondroitin Polymers 0.000 claims 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 85
- 210000002950 fibroblast Anatomy 0.000 description 21
- 238000001727 in vivo Methods 0.000 description 16
- 238000000338 in vitro Methods 0.000 description 13
- 210000001612 chondrocyte Anatomy 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000001413 cellular effect Effects 0.000 description 8
- 239000007943 implant Substances 0.000 description 8
- 238000004108 freeze drying Methods 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 6
- 239000002245 particle Substances 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 210000000845 cartilage Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- HGAZMNJKRQFZKS-UHFFFAOYSA-N chloroethene;ethenyl acetate Chemical compound ClC=C.CC(=O)OC=C HGAZMNJKRQFZKS-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000005012 migration Effects 0.000 description 4
- 238000013508 migration Methods 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 102000037983 regulatory factors Human genes 0.000 description 4
- 108091008025 regulatory factors Proteins 0.000 description 4
- 229910052710 silicon Inorganic materials 0.000 description 4
- 239000010703 silicon Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000003458 metachromatic effect Effects 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 2
- 229940094517 chondroitin 4-sulfate Drugs 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 102000038379 digestive enzymes Human genes 0.000 description 2
- 108091007734 digestive enzymes Proteins 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000000224 granular leucocyte Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000002648 laminated material Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000011164 ossification Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 241000486679 Antitype Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010011008 Chalones Proteins 0.000 description 1
- 108090000819 Chondroitin-sulfate-ABC endolyases Proteins 0.000 description 1
- 102000037716 Chondroitin-sulfate-ABC endolyases Human genes 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- -1 DNaεe Proteins 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 102400001368 Epidermal growth factor Human genes 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- MVORZMQFXBLMHM-QWRGUYRKSA-N Gly-His-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CN=CN1 MVORZMQFXBLMHM-QWRGUYRKSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 108010059712 Pronase Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- VSYMNDBTCKIDLT-UHFFFAOYSA-N [2-(carbamoyloxymethyl)-2-ethylbutyl] carbamate Chemical compound NC(=O)OCC(CC)(CC)COC(N)=O VSYMNDBTCKIDLT-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 210000002469 basement membrane Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229920013641 bioerodible polymer Polymers 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 210000002449 bone cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000022159 cartilage development Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229940047120 colony stimulating factors Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- QTCANKDTWWSCMR-UHFFFAOYSA-N costic aldehyde Natural products C1CCC(=C)C2CC(C(=C)C=O)CCC21C QTCANKDTWWSCMR-UHFFFAOYSA-N 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000001162 elastic cartilage Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000000913 erythropoietic effect Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 210000002219 extraembryonic membrane Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960004198 guanidine Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003035 hyaline cartilage Anatomy 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000003116 impacting effect Effects 0.000 description 1
- 238000012606 in vitro cell culture Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- ISTFUJWTQAMRGA-UHFFFAOYSA-N iso-beta-costal Natural products C1C(C(=C)C=O)CCC2(C)CCCC(C)=C21 ISTFUJWTQAMRGA-UHFFFAOYSA-N 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000002138 osteoinductive effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000007390 skin biopsy Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/02—Prostheses implantable into the body
- A61F2/022—Artificial gland structures using bioreactors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
- A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
- A61L27/3608—Bone, e.g. demineralised bone matrix [DBM], bone powder
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M35/00—Means for application of stress for stimulating the growth of microorganisms or the generation of fermentation or metabolic products; Means for electroporation or cell fusion
- C12M35/08—Chemical, biochemical or biological means, e.g. plasma jet, co-culture
Definitions
- BACKGROUND OF THE INVENTION Tran ⁇ differentiation or induction occurs when cells of one phenotype are transformed, in the presence of one or more growth and differentiation factors, into cells of another phenotype.
- One example is the response of connective tissue to demineralized bone powder.
- demineralized bone powder connective tissue cells are converted to chondroblasts, and produce a cartilage matrix that is resorbed and replaced by bone.
- the present invention features a device and method for inducing cell dif erentiation.
- One embodiment of the present invention features a device comprising a wall having an interior surface and an exterior surface. The interior surface defines a chamber. The exterior surface is capable of being placed in contact with biological tissues.
- the wall has an opening in communication with the chamber for receiving an induction material and for closing the chamber to contain the induction material.
- the wall comprises a biologically compatible, permeable material capable of receiving cells capable of differentiation.
- the device is used to contain an induction material in a biological environment and receiving cells in the chamber. The cells are allowed to differentiate in the presence of the induction material.
- the wall and opening comprise a first wall section and a second wall section.
- the first wall section has a chamber area for receiving an induction material and a peripheral edge area.
- the second wall section has a cooperating peripheral edge area capable of being received by the peripheral edge area of the first wall section to form the chamber.
- the housing has two ends. At least one end has a planar edge to allow the housing to stably rest on flat surfaces.
- the housing has conduits extending from the outer surface to the inner surface to allow the cavity to be in fluid communication with the environment at the outer surface when the housing is resting on the planar edge.
- the edge opposite said planar edge is open to allow cells and other materials to be placed on the exterior surface of the wall.
- One cell induction device of the present invention comprises a laminate including first and second layers of a structural matrix material.
- Each of the layers has an exterior and an interior peripheral surface.
- the interior peripheral surfaces of each of the first and second layers are engaged with each other in facing relationship. Engagement of the interior peripheral surfaces in this way defines a chamber between the two layers.
- the chamber is substantially free of structural matrix material.
- the engaged peripheral surfaces define a seam extending around the outer periphery of the laminate.
- a substrate capable of inducing growth and/or differentiation of one or more cells is disposed within the chamber in an amount sufficient to optimize the density of substrate within the chamber.
- the laminate is preferably permeable and biocompatible with the substrate.
- the substrate is preferably a material that is capable of inducing transdifferentiation of one or more cell ⁇ .
- the substrate is an osteogenic material.
- the substrate is demineralized bone powder and the structural matrix is a structural protein such as collagen.
- the cell induction device can further include a support for the laminate, this support being engaged with the peripheral seam of the laminate.
- the supporting structure is an annular collar having opposed ends, the peripheral seam of the laminate being attached to the inner peripheral ⁇ urface of the annular collar. Most preferably, the laminate seam is attached between the opposed end ⁇ of the collar.
- One end of the collar includes a plurality of conduits for transferring culture media (i.e. cells to be cultured such as connective tissue) into the interior of the collar.
- the invention includes a device for implanting into a subject.
- the device comprises a laminate including first and second layers of a permeable structural matrix.
- Each of the layers has an exterior and interior peripheral surface, the interior peripheral surfaces of said first and second layers are engaged together in facing relationship, defining a substantially hollow chamber that lacks the structural matrix.
- a substrate is disposed within the chamber, the substrate having inducing activity towards one or more cells that come in contact with the laminate.
- a plurality of induced cells is engaged with the laminate, some of said cells having been induced prior to implantation of the device,
- the invention also pertains to a method for analyzing the inductive activity of cells.
- the method includes the step of providing a laminate including first and second layers of structural matrix material, each of the layers having an exterior and interior peripheral surface. The interior peripheral surfaces of the first and second layers are engaged in facing relationship to each other to define a substantially hollow chamber that is substantially free of the matrix.
- a substrate is disposed within the chamber and the substrate is allowed to contact cells that are capable being induced in the presence of the substrate.
- the laminate is incubated in the presence of these cells for time sufficient for the cells to be induced by the substrate (i.e. to grow and/or differentiate) .
- the method also can include adding at least one cell growth factor and/or one glycosoaminoglycan to the laminate.
- the substrate is demineralized bone powder.
- the invention also pertains to methods of forming the device of the present invention.
- the method includes the step ⁇ of providing a mold comprising a tube having opposed ends.
- a first solution of structural matrix material is deposited into the bottom of the tube mold and frozen.
- a spacer is placed on top of the frozen matrix, but allowing a small uncovered peripheral edge of the matrix to remain exposed.
- the spacer and matrix are again frozen and a second amount of structural matrix material deposited on top of the spacer.
- a second spacer is placed over the second structural matrix material and the entire mold is lyophilized. After lyophilization, the spacers are carefully removed from the structural matrix to produce a laminate including first and second layers, each of the layers having exterior and interior peripheral surfaces.
- the spacers prevent formation of a denser, impermeable layer over the laminate.
- the interior peripheral surfaces of each of the layers sheets are engaged in facing relationship to define a peripheral seam.
- the laminate further defines a hollow chamber that is substantially free of the structural matrix material.
- a substrate is disposed between the layers of the laminate.
- the laminate containing the substrate is engaged with a support by engaging the peripheral seam of the laminate with a receiving means in the support.
- Figure 2 is a schematic, cross-sectional view of a method and apparatus for making the laminate of the invention
- Figure 3 is a schematic, cross-sectional view of the laminate of the invention engaged with a support device.
- the present invention involves a three-dimensional laminate and it ⁇ use as the framework for a three-dimensional, cell induction device.
- This device simulates physiologic conditions found in vivo to a greater degree than previously described systems.
- the device is applicable to the growth of different types of cells and tc the formation of a number of different tissues, including but not limited to bone, and connective tissue.
- the device has a variety of applications.
- the device may be transplanted from an in vitro situation to a living organism In vivo or implanted directly into a living organism.
- proliferating cells can be isolated from the device for transplantation.
- the device may also be used _in vitro for cytotoxicity testing and screening compounds.
- the device may be used as a "bioreactor" to produce cellular products in quantity.
- a substrate capable of promoting induction of one or more target cells is disposed into a chamber of a pree ⁇ tablished, three-dimensional laminate structure.
- induction refers to the growth and/or differentiation of a target cell; in particular the term “inductive” refers to substrates capable of promoting transdifferentiation processes such as, for example, the phenotypic transformation of mesenchyme cells (e.g., fibroblasts) into cartilage-producing chondroblasts.
- the chamber is formed by a three-dimensional laminate with or without additional cells and/or elements, described more fully herein.
- Materials of the laminate can support the growth of many different cells and tissues in the three-dimensional culture system. Once formed, the substrate is disposed within the three-dimensional laminate. Other growth and regulatory factors may also be added to the laminate.
- the laminate 10 includes first 12 and second 14 layers of structural matrix material.
- matrix means a material that can be visually homogenous, but preferably is granulated, fibrillar and/or filamentous in structure.
- Each of the first and second layers has an exterior peripheral surface, 16, 18 respectively.
- Each of the layers has interior peripheral surfaces, 17, 19, respectively.
- the interior peripheral surfaces 17, 19 of the first and second layers are engaged together in facing relationship to form a seam 21.
- the seam 21 extends substantially around the entire periphery of the laminate.
- a substantially hollow chamber 20 is defined between surfaces 17 and 19 chamber 20 is substantially free of the structural matrix material.
- a substrate 22 is disposed within chamber 20. The substrate 22 is capable of inducing growth and/or differentiation of one or more cells (not shown) .
- the structural matrix of the invention is permeable to the environment of use.
- permeable it is meant that the laminate will allow ingress and egress of materials (e.g. target cells, target cell fragment, blood vessels, bodily fluids) without restricting these materials to any particular molecular weight or size. This property is to be distinguished from well-known semipermeable or selectively permeable membranes that discriminate according to molecular weight and/or size.
- materials e.g. target cells, target cell fragment, blood vessels, bodily fluids
- the permeable nature of the present laminates fosters the development of a microenvironment within the laminate that simulates _in vivo conditions.
- the laminate of the present invention must also be biocompatible with the substrate.
- Conventional cell culture devices particularly if they are implanted in vivo, are typically implants in which cells or cellular products are released from the implant to act on a distant target. The biocompatability of these structures is tested by assaying the implants for the presence of inflammatory cells (i.e. foam cell ⁇ , polymorphonuclear leukocytes, macrophage ⁇ , and the like) after 7 day ⁇ . If the a ⁇ say is negative (i.e. no inflammatory cells are present in the implant), the implant material is considered biocompatible.
- inflammatory cells i.e. foam cell ⁇ , polymorphonuclear leukocytes, macrophage ⁇ , and the like
- biocompatible laminates require target cells to be induced within the laminate itself so that the action of the substrate on the target cells is not at a distance.
- biocompatible in the present context, is stricter and refers to the ability of the laminate to maintain the biological integrity of the substrate.
- a biocompatible laminate must: (i) not directly inhibit the substrate's ability to attract structures such as, for example, blood vessels, or to induce one or more cells; and/or (ii) prevent inflammatory cell ⁇ from compromising the substrate's ability to attract or induce one or more cells.
- preferred laminate ⁇ of the invention are considered biocompatible with a substrate if a transient infiltrate of polymorphonuclear leukocytes is not observed after 2 days jin vivo.
- the in vivo biocompatability of a given laminate can be easily tested by preparing the laminate and the enclosed substrate and histologically examining the laminate for the presence of inflammatory cells and correlating the hi ⁇ tological examination with assays of inductive activity.
- Disposition of the substrate inside the hollow chamber will sustain active proliferation and differentiation of cells in culture for much longer time periods than will homogeneous dispersion of substrate throughout the structural matrix material itself.
- the chamber allows for a biomimetic spatial distribution of substrate (i.e. a substrate distribution analogous to that found in the counterpart tissue in vivo) .
- the increase in potential volume for particulate substrates in the chamber may allow the establishment of a particulate substrate packing density conducive to growth and/or differentiation of cell ⁇ . That is, it is believed that the disposition of particulate substrates within the chamber optimizes cell-substrate interactions by allowing greater packing of cells and substrate in the chamber.
- the laminate lacks any impermeable portions that would prevent infiltration of fluids, cell ⁇ , or other structures (e.g. blood vessels) into the chamber.
- a number of materials are suitable for the laminates of the present invention.
- the preferred laminates should:
- a number of permeable materials may be used to form the matrix, including but not limited to: minerals (e.g. hydroxyapatite, aragonite), ceramics, glasses, dacron (polyesters), polytetrafluorothylene (PTFE; teflon), nitrocellulose, cotton, cellulose, gelatin, dextran, etc.
- minerals e.g. hydroxyapatite, aragonite
- ceramics e.g. hydroxyapatite, aragonite
- glasses dacron (polyesters), polytetrafluorothylene (PTFE; teflon), nitrocellulose, cotton, cellulose, gelatin, dextran, etc.
- PTFE polytetrafluorothylene
- Type I found in fibroblasts, bone, dentin and connective tissue
- Type II found in hyaline and elastic cartilage
- Type III found in blood ve ⁇ el ⁇
- Type IV found in basement membranes
- Type V found in bone, smooth muscle and fetal membranes.
- Type I is preferred for the laminate of the present invention.
- a substrate capable of inducing growth and/or differentiation of one or more cell ⁇ , with or without other cells and elements described below, is disposed into the chamber.
- the substrate may be derived from cells or tissues which can be obtained by biopsy (where appropriate) or upon autopsy.
- the substrate is a material which can induce growth and/or differentiation of one or more cell types.
- General substrates of this category include, but are not limited to: (i) osteogenic; (ii) angiogenic; (iii) adipogenic; or (iv) hematopoietic substrates.
- Specific substrates that have these respective characteristics include: (i) demineralized bone powder (DBP)-capable of inducing, for example, rnesenchyme cells such as fibroblasts, to form chondroblast ⁇ ; (ii) heparan sulfate- capable of inducing blood vessel formation; (iii) steroid-producing cells- capable of converting fibroblasts to adipose tissue; and (iv) extracellular matrix of bone marrow connective tissue cells- capable of converting target cells into blood cell ⁇ .
- DBP demineralized bone powder
- the substrate has a concentration chosen to optimize its packing density in the chamber.
- the packing density of the substrate is important in determining its inducing ability. Differentiation of fibroblasts into chondrobla ⁇ ts often occurs between adjacent particles of DBP. For a laminate about 3/8" in diameter, about lOmg of DBP i ⁇ optimal. Those of ordinary ⁇ kill in the art can readily determine the optimum amount of other substrates by assaying the relationship between sub ⁇ trate amount and the inducing -li ⁇
- cells found in loose connective tissue may be inoculated into the laminate.
- Such cells include, but are not limited to endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocyte ⁇ , o ⁇ teoblast ⁇ , and bone marrow stromal cells. These cells may readily be derived from appropriate organs such as skin, liver etc., using methods known in the art.
- Other cells can include prokaryotic cell ⁇ , eukaryotic cells, and recombinantly engineered cells.
- the growth of cell ⁇ in the presence of the substrate may be further enhanced by adding to the laminate glycoproteins (such as, for example, bone morphogenic protein), glycosaminoglycans (e.g., heparan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate, etc.) cellular matrix, and/or other materials.
- glycoproteins such as, for example, bone morphogenic protein
- glycosaminoglycans e.g., heparan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate, etc.
- growth factors may be used to enhance, alter, or modulate proliferation and cell maturation in the cultures.
- the growth and activity of cells in culture can be affected by a variety of growth factors such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta) ,insulin, growth hormone, ⁇ omatomedin ⁇ , colony stimulating factors, erythropoietin, epidermal growth factor, hepatic erythropoietic factor (hepatopoietin) , and liver-cell growth factor.
- PDGF platelet-derived growth factor
- TGF-beta transforming growth factor-beta
- insulin growth hormone
- ⁇ omatomedin ⁇ colony stimulating factors
- erythropoietin epidermal growth factor
- hepatic erythropoietic factor hepatopoietin
- liver-cell growth factor Other factors which regulate proliferation and/or differentiation include ⁇ teroid ⁇ pro ⁇ taglandins, interleukins, vitamins, and naturally-occurring chalones .
- transdifferentiation of fibroblasts or bone marrow cells can be modulated by steroids so that the fibroblasts or bone marrow is transformed into adipocyte ⁇ , instead of chondrocytes.
- the laminate i ⁇ incubated in an appropriate nutrient medium containing one or more cells capable of growth and/or differentiation under the influence of the substrate.
- an appropriate nutrient medium containing one or more cells capable of growth and/or differentiation under the influence of the substrate.
- Many commercially available media such as RPMI 1640, Fisher's, Iscove's, McCoy' ⁇ , and the like may be suitable for use.
- the laminate can be suspended or floated in the medium during the incubation period in order to maximize proliferative and/or differentiation activity.
- the culture should be fed periodically to remove the spent media, depopulate released cells, and add fresh media.
- Fibroblasts are prepared and added to the laminate. Fibroblasts may be readily isolated by disaggregating an appropriate organ or tissue which is to serve as the source of the fibroblasts. This may be readily accomplished using techniques known to those skilled in the art.
- the tissue or organ can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage. Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with any of a number of digestive enzymes either alone or in combination.
- tissue disaggregation techniques see Fre ⁇ hney, Culture of Animal Cell ⁇ , A Manual of Basic Technique, 2d Ed., A.R. Li ⁇ , Inc. New York, 1987, Ch. 9, pp. 107-126.
- a unique feature of the pre ⁇ ent invention i ⁇ the manner and apparatus used to fabricate the laminated cell culture device of the invention.
- a mold made of an inert elastomer i.e. Tygon® tubing
- FIGURE 2 illustrates a preferred mold and laminate in an intermediate step in the manufacturing process.
- the mold 30 is a substantially annular collar 32 having opposed ends 34, 36.
- 3/8" Tygon® tubing is cut into approximately 1 cm pieces.
- One end 36 of the tube is closed off by gluing the tube on a tissue culture dish 31 with, for example. Medical Adhesive Silicon (Dow Corning). The molds are dried.
- a preferred laminate is formed by providing a first solution 38 (up to several hundred microliters) of structural protein (i.e. a collagen matrix) to the closed end 36 of mold 30. Between 80-200 microliters of structural protein solution is optimal for the preferred laminate structures of the invention.
- structural protein i.e. a collagen matrix
- the mold is then frozen.
- a spacer 40 (preferably wet paper) is placed on top of the frozen matrix 38, but the peripheral edges of the matrix remain exposed.
- the spacer 40 and matrix 38 are again frozen and a second amount of structural protein matrix 42 (up to several hundred microliters) deposited on top of spacer 40.
- a second spacer 44 is placed over the second structural protein matrix 42. The peripheral edges of the second matrix do not need to remain exposed.
- the entire mold is lyophilized.
- the spacers are carefully removed from the structural protein matrix.
- the interior peripheral surfaces of the layers spontaneou ⁇ ly ⁇ eal or otherwi ⁇ e anneal together during the lyophilization procedure to form a seam, defining a substantially hollow chamber that is substantially free of the structural matrix material.
- This seam extends sub ⁇ tantially around the entire outer periphery of the laminate (See FIGURE 1).
- the use of the spacers eliminates development of an impermeable, dense shell of protein that typically forms during lyophilization. Lyophilization provides enough strength to the laminate to allow for ease of handling and packing of the laminate.
- a preferred substrate is demineralized bone powder, prepared from cortical sections of femoral and tibial bones (i.e. rat) (See Example 1).
- the bone is extracted with an alcohol solvent (i.e. ethanol) and an ether solvent.
- the dehydrated bone is frozen and pulverized in, for example, a liquid nitrogen impacting mill (Spex Industries, Metuchen, NJ) . Bone pieces are seived and collected, preferably as a fraction between 75 and 250 um.
- Mineral extraction i ⁇ performed with acid (i.e. 0.5 HC1) for several hours at room temperature. Final drying is achieved by solvent washing, as above.
- the laminate containing the substrate is secured to a support device.
- the support device is substantially identical to the manufacturing mold with the addition of several features.
- Figure 3 illustrates a support 50 after the substrate 22 has been disposed into chamber 20.
- a plurality of conduits 52 has been cut into one end 54 of 3/8" Tygon tubing.
- the conduits provide for entry of culture fluid from outside the support.
- the opposed end 55 of support 50 receives the target cells (not shown) and the space 57 defined by laminate's peripheral surface 16, the inner periphery 60 of the support 50, and end 55, preferably serves as a receptacle for target cells so that they may infiltrate and migrate into the laminate.
- a pair of opposed flanges 56, 58 or silicon O-rings is placed on the inner periphery 60 of support 50.
- the flanges 56,58 are in facing relationship to each other.
- the opposed flanges on the inner periphery 60 of the support 50 receives the peripheral seam 21 of the laminate.
- Silicon tubing (about 3/8" in diameter, 1/16" wall thickness, 1.5mm in length) is preferably used to make the flanges. The silicon tubing is fit in place on the inner periphery 60 of support 50.
- the support containing the laminate packed with substrate can be used in the preliminary stages of in vitro cell culture to provide a stable receptacle and platform for the migration, growth, and differentiation of one or more cells. It will be understood that a variety of other laminate configurations can be fabricated using the present methods. For example, a multichamber laminate can be easily fabricated using several spacers and more than two layers of structural matrix material. Each chamber can be charged with the same, or different, substrate.
- the device of the invention can be used in a variety of applications. These include, but are not limited to, transplantation or implantation of the laminate in vivo; screening differentiation inducing factors, cytotoxic compounds, allergen ⁇ , growth/regulatory factors, pharmaceutical compounds, etc., iji vitro; studying the mechanism by which drugs and/or growth factors operate; and the production of biologically active product ⁇ , to name but a few.
- either the cells obtained from the laminate or the entire laminate could be implanted, depending upon the type of tissue involved.
- a subject i.e. an animal, preferably a mammal such as a human
- the cells obtained from the laminate or the entire laminate could be implanted, depending upon the type of tissue involved.
- three-dimensional bone cultures can be maintained in vitro for long periods; the cells isolated from the ⁇ e culture ⁇ can be u ⁇ ed in tran ⁇ plantation or the entire laminate may be implanted.
- Three-dimensional tissue culture implants may, according to the invention, be used to replace or augment existing tissue, to introduce new or altered tissue, to modify artificial prostheses, or to join together biological tissues or structures.
- specific embodiments of the invention would include (i) removal of cells from a subject (i.e.
- fibroblasts from a human skin biopsy sample
- in vitro induction of these cells to form chondroblasts and production of three-dimensional bone culture implants used vivo in the same subject to replace bone destroyed during chemotherapeutic treatment
- genetically altering cells grown in three-dimensional culture for example to produce three-dimensional cultures of chondroblasts which express a recombinant gene encoding a therapeutic agent, and their use jn vivo to replace bone destroyed during chemotherapeutic treatment.
- the device may be used j vitro to screen a wide variety of putative substrates and growth/regulatory factors.
- cell cultures are maintained in vitro and exposed to a particular substrate suspected of having inducing activity.
- Response of the cell culture is assayed using conventional methods (see, Example 1).
- the ability of compounds to modulate (i.e. enhance or suppress) inductive activity can also be measured by, for example, vital staining techniques or by analyzing the cellular contents of the laminate e.g., by total cell counts, and differential cell counts. This may be accomplished using standard cytological, biochemical and/or histological techniques, including the use of immunocytochemical techniques employing antibodies that define type-specific cellular antigen ⁇ .
- the effect of variou ⁇ drugs on cells cultured in the device may also be assessed. For example, drugs that increase bone and/or cartilage formation can be tested on chondrobla ⁇ t cultures.
- the device of the invention can also be used to study and as ⁇ e ⁇ s the biocompatability of various structural matrix materials.
- Laminates can be fabricated of the material to be tested and the laminate charged with a particular substrate. The effect of different laminate materials on the inductive capacity of the sub ⁇ trate can be a ⁇ ayed u ⁇ ing the method ⁇ de ⁇ cribed herein.
- the device of the invention may be used as a model system for the study of physiologic or pathologic conditions.
- a laminate may be used as a model for a bone sy ⁇ tem can be used to study the penetration of sub ⁇ tance ⁇ through bone, and/or a ⁇ a model system to study the effect of bone tran ⁇ differentiation factors.
- variou ⁇ specialized cells may be added to the device.
- the long-term growth of bone cells in the laminate may be enhanced by the addition of certain mononuclear cell populations or by the addition of growth factor ⁇ to the culture medium.
- the device has utility In vitro to produce biological product ⁇ in high yield.
- a differentiated cell which, in the presence of the substrate, produces large quantities of a particular biological product could be grown using the device and the product can be trapped and isolated within the laminate material (e.g., extracellular matrix, cell-surface-associated products) .
- Differentiated cells which produce more soluble products (e.g. growth factor ⁇ , regulatory factors, peptides, hormones, etc.), can also be grown.
- the product can be isolated from the laminate, into the nutrient medium, the product may be readily isolated from the laminate or medium using standard separation techniques (e.g., HPLC, column chromatography, electrophoretic techniques, to name but a few).
- standard separation techniques e.g., HPLC, column chromatography, electrophoretic techniques, to name but a few.
- a "bioreactor" could be thereforedevi ⁇ ed which would take advantage of a continuous flow method for feeding the laminate in vitro for the production of, for example, extracellular matrix or cell-surface-associated products of target cells.
- a kit for in vitro studies will comprise the laminate of the invention having a ⁇ ub ⁇ trate di ⁇ posed within the chamber, the substrate specific for growing and/or differentiating cells of interest; cell ⁇ of interest seeded on the laminate; and reagents for determining the effects of a given compound on growth and/or differentiation of the cells of interest.
- the laminate i ⁇ a collagen matrix and the substrate is DBP.
- Type 1 soluble collagen solution for example, Celiagen® (Cat. # PC-5 -ICN Biomedicals, CA) , was used for the laminate construction. This consists of purified insoluble type 1 collagen extracted from calf dermis that has been solubilized by pepsin treatment in order to neutralize this collagen solution. About 1/100 of the final volume of 1 M H ⁇ PES [pH 7.4 (final 10 mM) ] and the same volume of 1 M NaHCO_(final 10 mM) were added to the collagen solution. Next, about 120 microliters of 0.5% collagen ⁇ olution (ICN Biomedical ⁇ , IL) was poured into the mold and frozen at -20°C.
- Celiagen® Cat. # PC-5 -ICN Biomedicals, CA
- the concentration of collagen can vary since poro ⁇ ity of the final matrix i ⁇ a function of the collagen concentration ⁇ .
- a 0.5% pepsin-digested collagen solution which is ph 3 in acetic acid is most preferred.
- the concentration can be greater than 0.5%, although concentrations much less than 0.3% will not yield a strong enough collagen matrix.
- a wet folded piece of paper was placed on the top surface of the frozen collagen, but allowing a small, uncovered edge of the laminate to remain exposed.
- Demineralized bone powder (DBP) wa ⁇ prepared according to standard protocols. Briefly, mammalian bones, for example diaphyseal bone ⁇ from cow ⁇ , are stripped of muscle and fat, cleaned of periosteum, demarrowed by pressure and cold water, and dried and fragmented by crushing and pulverizing in a large mill. Care is taken to prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size between about 75-250 microns . The bone powder is then demineralized with 20 volumes of 0.5N HCl at 4 C for about 24 hours. The acid i ⁇ removed every eight hours and fresh acid is added.
- mammalian bones for example diaphyseal bone ⁇ from cow ⁇ , are stripped of muscle and fat, cleaned of periosteum, demarrowed by pressure and cold water, and dried and fragmented by crushing and pulverizing in a large mill. Care is taken to prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size
- the DBP i ⁇ rendered inactive by dissociate extraction with 20 volumes of 4M guanidine-HCl.
- the solid material i ⁇ then wa ⁇ hed with water, wa ⁇ hed with one volume of absolute ethanol and dehydrated with one volume of anhydrous ether.
- Human dermal fibroblasts were isolated by explant culture in DMEM with 10% FBS and antibiotics.
- Human costal chondrocytes (used as positive controls) were isolated by collagenase digestion and cultured in Ham's F-12 with 10% FBS and antibiotics.
- Bovine articular chondrocytes were also used as a positive control.
- About 1x10° target cells were introduced into the open end of the support and allowed to contact the laminate on its upper peripheral surface. In others, cells were inoculated directly into the laminate. After overnight incubation, the laminates were cultured in the molds in a vertical position for achieving effective nutrient exchange. After 3 days, the laminates were removed from the mold and the laminates only were subsequently incubated. Media were changed twice weekly. On days 7 or 10, laminates were harvested and fixed in 2% paraformaldehyde, as described below.
- Laminates with/without DBP or guanidine-extracted DBP residue were deposited in subcutaneous pockets in 28-day-old rats. Laminates were harvested at intervals, fixed in 2% parafcrmaldehyde, and embedded in giycol methacrylate (JB-4) or paraffin. A series of twentv- icron sections were stained with toluidine blue, enabling visualization of metachromatic matrix around cell ⁇ . The twenty-micron ⁇ ection ⁇ were blocked with 5% normal goat serum and stained with various amounts (1:100 to 1:1000 dilution) of monoclonal antibodies against chondroitin sulfate: CS-56 (ICN Biomedicals, Cat.
- D type (MO-225: Seikagaku America, Cat. tt 270802), anti-type II collagen (Chemicon Co., Cat. # MAB1330), keratan sulfate (Seikagaku, Cat. # 270786), anti-proteoglycan ( ⁇ Di-OS: Seikagaku, Cat. 8 270788), ⁇ Di-6S: Seikagaku, Cat. tt 270789), and ⁇ Di-4S:Seikagaku, Cat. tt 270790) after chondroitinase ABC digestion.
- the silver-enhanced immunogold procedure was used (AuroProbe LM R, Janssen Biotech NV, Belgium) .
- DBP laminates prepared as described were not inflammatory, permitted substantial vascularization, provided a scaffold for cellular migration, and induced endochondral osteogenesis.
- chondrocyte-bearing laminates In chondrocyte-bearing laminates, cells infiltrated the collagen network and attached to both DBP and DBP residue. By day 3, metachromatic granular deposits surrounded chondrocytes with immunohistochemical reactivity with cartilage-specific antibodies. In fibroblast-bearing laminates, migration and viability were equivalent with DBP and DBP residue. Fibroblasts were attached to the collagen network and to the particles with evidence of ECM synthesis. Metachromasia and immunoreactivity with cartilage-specific antibodies were not seen around fibroblasts on the collagen laminate nor on the DBP residue. In contrast, fibroblasts in close approximation with DBP were surrounded by metachromatic, immunoreative matrix, similar to that around bonafide chondrocytes.
- Anti-keratan sulfate antibodies showed intense staining in and around human chondrocytes attached to the laminate and between DBP particles. Cartilage-specific antibodies were reactive with human fibroblasts on DBP. Also, antibody to chondroitin-4 sulfate was positive for cell ⁇ on DBP and negative for cell ⁇ on guanidine-extracted DBP or collagen alone.
Abstract
The present invention features a device and method for inducing cell differentiation. One embodiment of the present invention features a device comprising a wall having an interior surface and an exterior surface. The interior surface defines a chamber. The exterior surface is capable of being placed in contact with biological tissues. The wall has an opening in communication with the chamber for receiving an induction material and for closing the chamber to contain the induction material. The wall comprises a biologically compatible, permeable material capable of receiving cells capable of differentiation. The device is used to contain an induction material in a biological environment and receiving cells in the chamber. The cells are allowed to differentiate in the presence of the induction material.
Description
CELL INDUCTION DEVICE
This work was sponsored in part by National Institutes of Health Grant ttCA 45548 to JG. The U.S. Government may have certain rights to this invention.
BACKGROUND OF THE INVENTION Tranεdifferentiation or induction occurs when cells of one phenotype are transformed, in the presence of one or more growth and differentiation factors, into cells of another phenotype. One example is the response of connective tissue to demineralized bone powder. In the presence of demineralized bone powder, connective tissue cells are converted to chondroblasts, and produce a cartilage matrix that is resorbed and replaced by bone.
Devices used for the study of transdifferentiation have often relied upon semipermeable membranes as a support for the required growth and differentiation factor(s) and for the cells that are acted upon by these factors. These semipermeable membranes often induce an inflammatory response in a subject when implanted in vivo. Moreover, _in vivo assays designed to test the ability of growth and differentiation factors, and other molecules that modulate this activity, are often expensive, cumbersome, and time-consuming. Furthermore, prior culture devices have suffered from problems associated with dispersion of growth and differentiation factors on the surface of a support. The factors are ineffective because the levels in the support are too low to cause the desired effect. As a result, _in vitro systems for promoting transdifferentiation and in vivo implants designed to induce tranεdifferention have been generally ineffective.
SUMMARY OF THE INVENTION The present invention features a device and method for inducing cell dif erentiation. One embodiment of the present invention features a device comprising a wall having an
interior surface and an exterior surface. The interior surface defines a chamber. The exterior surface is capable of being placed in contact with biological tissues. The wall has an opening in communication with the chamber for receiving an induction material and for closing the chamber to contain the induction material. The wall comprises a biologically compatible, permeable material capable of receiving cells capable of differentiation. The device is used to contain an induction material in a biological environment and receiving cells in the chamber. The cells are allowed to differentiate in the presence of the induction material.
In one preferred embodiment of the device the wall and opening comprise a first wall section and a second wall section. The first wall section has a chamber area for receiving an induction material and a peripheral edge area. The second wall section has a cooperating peripheral edge area capable of being received by the peripheral edge area of the first wall section to form the chamber.
One embodiment of the present device features a support . The support engages the peripheral edge areas of the first and second wall sections to provide closure of the edge areas and to facilitate handling. Preferably, the support comprises a housing. The housing has an inner surface and an outer surface. The inner surface defines a cavity having a groove for engaging the first and second wall sections. Preferably, the groove is defined by cooperating flanges projecting inwardly in spaced relationship.
Preferably, the housing has two ends. At least one end has a planar edge to allow the housing to stably rest on flat surfaces. The housing has conduits extending from the outer surface to the inner surface to allow the cavity to be in fluid communication with the environment at the outer surface when the housing is resting on the planar edge.
The edge opposite said planar edge is open to allow cells and other materials to be placed on the exterior surface of the wall.
One cell induction device of the present invention comprises a laminate including first and second layers of a structural matrix material. Each of the layers has an exterior and an interior peripheral surface. The interior peripheral surfaces of each of the first and second layers are engaged with each other in facing relationship. Engagement of the interior peripheral surfaces in this way defines a chamber between the two layers. The chamber is substantially free of structural matrix material. The engaged peripheral surfaces define a seam extending around the outer periphery of the laminate.
A substrate capable of inducing growth and/or differentiation of one or more cells is disposed within the chamber in an amount sufficient to optimize the density of substrate within the chamber. The laminate is preferably permeable and biocompatible with the substrate.
The substrate is preferably a material that is capable of inducing transdifferentiation of one or more cellε. Most preferably, the substrate is an osteogenic material. In particularly preferred embodiments of the invention, the substrate is demineralized bone powder and the structural matrix is a structural protein such as collagen.
The cell induction device can further include a support for the laminate, this support being engaged with the peripheral seam of the laminate. The supporting structure is an annular collar having opposed ends, the peripheral seam of the laminate being attached to the inner peripheral εurface of the annular collar. Most preferably, the laminate seam is attached between the opposed endε of the collar. One end of the collar includes a plurality of conduits for transferring culture media (i.e. cells to be cultured such as connective tissue) into the interior of the collar.
The invention includes a device for implanting into a subject. The device comprises a laminate including first and second layers of a permeable structural matrix. Each of the layers has an exterior and interior peripheral surface, the interior peripheral surfaces of said first and second layers are engaged together in facing relationship, defining a substantially hollow chamber that lacks the structural matrix. A substrate is disposed within the chamber, the substrate having inducing activity towards one or more cells that come in contact with the laminate. A plurality of induced cells is engaged with the laminate, some of said cells having been induced prior to implantation of the device,
The invention also pertains to a method for analyzing the inductive activity of cells. The method includes the step of providing a laminate including first and second layers of structural matrix material, each of the layers having an exterior and interior peripheral surface. The interior peripheral surfaces of the first and second layers are engaged in facing relationship to each other to define a substantially hollow chamber that is substantially free of the matrix. A substrate is disposed within the chamber and the substrate is allowed to contact cells that are capable being induced in the presence of the substrate. The laminate is incubated in the presence of these cells for time sufficient for the cells to be induced by the substrate (i.e. to grow and/or differentiate) . The method also can include adding at least one cell growth factor and/or one glycosoaminoglycan to the laminate. Preferably, the substrate is demineralized bone powder.
The invention also pertains to methods of forming the device of the present invention. The method includes the stepε of providing a mold comprising a tube having opposed ends. A first solution of structural matrix material is deposited into the bottom of the tube mold and frozen. A spacer is placed on top of the frozen matrix, but allowing a small uncovered peripheral edge of the matrix to remain
exposed. The spacer and matrix are again frozen and a second amount of structural matrix material deposited on top of the spacer. A second spacer is placed over the second structural matrix material and the entire mold is lyophilized. After lyophilization, the spacers are carefully removed from the structural matrix to produce a laminate including first and second layers, each of the layers having exterior and interior peripheral surfaces. The spacers prevent formation of a denser, impermeable layer over the laminate. The interior peripheral surfaces of each of the layers sheets are engaged in facing relationship to define a peripheral seam. The laminate further defines a hollow chamber that is substantially free of the structural matrix material. A substrate is disposed between the layers of the laminate. Optionally, the laminate containing the substrate is engaged with a support by engaging the peripheral seam of the laminate with a receiving means in the support.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a schematic, cross-sectional view of the laminate of the invention;
Figure 2 is a schematic, cross-sectional view of a method and apparatus for making the laminate of the invention; Figure 3 is a schematic, cross-sectional view of the laminate of the invention engaged with a support device.
DETAILED DESCRIPTION OF THE INVENTION The present invention involves a three-dimensional laminate and itε use as the framework for a three-dimensional, cell induction device. This device simulates physiologic conditions found in vivo to a greater degree than previously described systems. The device is applicable to the growth of different types of cells and tc the formation of a number of different tissues, including but not limited to bone, and connective tissue.
The device has a variety of applications. For example, the device may be transplanted from an in vitro situation to a living organism In vivo or implanted directly into a living organism. Alternatively, proliferating cells can be isolated from the device for transplantation. The device may also be used _in vitro for cytotoxicity testing and screening compounds. In yet another application, the device may be used as a "bioreactor" to produce cellular products in quantity.
In accordance with the invention, a substrate capable of promoting induction of one or more target cells is disposed into a chamber of a preeεtablished, three-dimensional laminate structure. The term "induction" refers to the growth and/or differentiation of a target cell; in particular the term "inductive" refers to substrates capable of promoting transdifferentiation processes such as, for example, the phenotypic transformation of mesenchyme cells (e.g., fibroblasts) into cartilage-producing chondroblasts.
The chamber is formed by a three-dimensional laminate with or without additional cells and/or elements, described more fully herein. Materials of the laminate can support the growth of many different cells and tissues in the three-dimensional culture system. Once formed, the substrate is disposed within the three-dimensional laminate. Other growth and regulatory factors may also be added to the laminate.
Referring to FIGURE 1, a laminate of the invention is shown. The laminate 10 includes first 12 and second 14 layers of structural matrix material. The term "matrix" means a material that can be visually homogenous, but preferably is granulated, fibrillar and/or filamentous in structure. Each of the first and second layers has an exterior peripheral surface, 16, 18 respectively. Each of the layers has interior peripheral surfaces, 17, 19, respectively. The interior peripheral surfaces 17, 19 of the
first and second layers are engaged together in facing relationship to form a seam 21. The seam 21 extends substantially around the entire periphery of the laminate.
A substantially hollow chamber 20 is defined between surfaces 17 and 19 chamber 20 is substantially free of the structural matrix material. A substrate 22 is disposed within chamber 20. The substrate 22 is capable of inducing growth and/or differentiation of one or more cells (not shown) .
The structural matrix of the invention is permeable to the environment of use. By "permeable" it is meant that the laminate will allow ingress and egress of materials (e.g. target cells, target cell fragment, blood vessels, bodily fluids) without restricting these materials to any particular molecular weight or size. This property is to be distinguished from well-known semipermeable or selectively permeable membranes that discriminate according to molecular weight and/or size. The permeable nature of the present laminates fosters the development of a microenvironment within the laminate that simulates _in vivo conditions.
The laminate of the present invention must also be biocompatible with the substrate. Conventional cell culture devices, particularly if they are implanted in vivo, are typically implants in which cells or cellular products are released from the implant to act on a distant target. The biocompatability of these structures is tested by assaying the implants for the presence of inflammatory cells (i.e. foam cellε, polymorphonuclear leukocytes, macrophageε, and the like) after 7 dayε . If the aεsay is negative (i.e. no inflammatory cells are present in the implant), the implant material is considered biocompatible.
In contrast, the present laminates require target cells to be induced within the laminate itself so that the action of the substrate on the target cells is not at a distance. The meaning of the term "biocompatible", in the present context, is stricter and refers to the ability of the
laminate to maintain the biological integrity of the substrate. Thus, a biocompatible laminate must: (i) not directly inhibit the substrate's ability to attract structures such as, for example, blood vessels, or to induce one or more cells; and/or (ii) prevent inflammatory cellε from compromising the substrate's ability to attract or induce one or more cells. In particular, preferred laminateε of the invention are considered biocompatible with a substrate if a transient infiltrate of polymorphonuclear leukocytes is not observed after 2 days jin vivo.
The in vivo biocompatability of a given laminate can be easily tested by preparing the laminate and the enclosed substrate and histologically examining the laminate for the presence of inflammatory cells and correlating the hiεtological examination with assays of inductive activity.
Disposition of the substrate inside the hollow chamber will sustain active proliferation and differentiation of cells in culture for much longer time periods than will homogeneous dispersion of substrate throughout the structural matrix material itself. Although the applicants are under no duty or obligation to explain the mechanism by which the invention works, a number of factors inherent in the three-dimensional culture may contribute to this:
(a) The chamber allows for a biomimetic spatial distribution of substrate (i.e. a substrate distribution analogous to that found in the counterpart tissue in vivo) .
(b) The increase in potential volume for particulate substrates in the chamber may allow the establishment of a particulate substrate packing density conducive to growth and/or differentiation of cellε. That is, it is believed that the disposition of particulate substrates within the chamber optimizes cell-substrate interactions by allowing greater packing of cells and substrate in the chamber.
(c) It has been recognized that maintenance of a differentiated cellular phenotype requires a favorable microenvironment for production of growth/differentiation
factorε. It is believed that the present device provides this microenvironment suitable for appropriate cellular interactions.
(d) The laminate lacks any impermeable portions that would prevent infiltration of fluids, cellε, or other structures (e.g. blood vessels) into the chamber.
The laminate matrix may be of any material: (a) that allows cells to attach to it (or can be modified to allow cells to attach to it); and (b) can be formed as a plurality of layers whose interior peripheral surfaces can naturally seal or anneal themselves together in facing relationship without use of adheεives, excipients, or other added materials, thus defining a chamber.
A number of materials are suitable for the laminates of the present invention. The preferred laminates should:
(i) have a a pH in vivo near, or above neutrality (between about 7.0 to about 8.0). This property tends to exclude bioerodible polymers such as polyglycolides or polylactideε, becauεe they appear to be acidic when implanted in vivo. The acidity of theεe polymers prevents migration of fibroblasts and differentiation into cartilage inside the laminates;
(ii) be permeable, rather than semipermeable and/or selectively permeable;
(iii) be biocompatible with the substrate in vitro and in vivo.
A number of permeable materials may be used to form the matrix, including but not limited to: minerals (e.g. hydroxyapatite, aragonite), ceramics, glasses, dacron (polyesters), polytetrafluorothylene (PTFE; teflon), nitrocellulose, cotton, cellulose, gelatin, dextran, etc. Provided that they meet the requirements set out above, any of theεe materials may be fabricated into a laminate.
However, the most preferred materialε for forming the laminate of the invention are structural proteins such as elastin fiberε, fibronectin, laminin and the like.
Particularly preferred materials for forming the laminate are collagens that have been treated so that they maintain porosity upon lyophilization and are not inflammatory r vivo,
There are five types of collagen known: Type I, found in fibroblasts, bone, dentin and connective tissue; Type II, found in hyaline and elastic cartilage; Type III, found in blood veεεelε; Type IV, found in basement membranes; and Type V, found in bone, smooth muscle and fetal membranes. Type I is preferred for the laminate of the present invention.
A substrate capable of inducing growth and/or differentiation of one or more cellε, with or without other cells and elements described below, is disposed into the chamber. The substrate may be derived from cells or tissues which can be obtained by biopsy (where appropriate) or upon autopsy. The substrate is a material which can induce growth and/or differentiation of one or more cell types. General substrates of this category include, but are not limited to: (i) osteogenic; (ii) angiogenic; (iii) adipogenic; or (iv) hematopoietic substrates. Specific substrates that have these respective characteristics include: (i) demineralized bone powder (DBP)-capable of inducing, for example, rnesenchyme cells such as fibroblasts, to form chondroblastε; (ii) heparan sulfate- capable of inducing blood vessel formation; (iii) steroid-producing cells- capable of converting fibroblasts to adipose tissue; and (iv) extracellular matrix of bone marrow connective tissue cells- capable of converting target cells into blood cellε.
The substrate has a concentration chosen to optimize its packing density in the chamber. The packing density of the substrate is important in determining its inducing ability. Differentiation of fibroblasts into chondroblaεts often occurs between adjacent particles of DBP. For a laminate about 3/8" in diameter, about lOmg of DBP iε optimal. Those of ordinary εkill in the art can readily determine the optimum amount of other substrates by assaying the relationship between subεtrate amount and the inducing
-li¬
ability of that substrate. In the case of DBP, packing density is optimized visually by making sure that each DBP particle is in physical contact with an adjacent DBP particle
In addition to the substrate, other materials may be added to the laminate to support long term growth and/or differentiation in culture. For example, cells found in loose connective tissue may be inoculated into the laminate. Such cells include, but are not limited to endothelial cells, pericytes, macrophages, monocytes, plasma cells, mast cells, adipocyteε, oεteoblastε, and bone marrow stromal cells. These cells may readily be derived from appropriate organs such as skin, liver etc., using methods known in the art. Other cells can include prokaryotic cellε, eukaryotic cells, and recombinantly engineered cells.
The growth of cellε in the presence of the substrate may be further enhanced by adding to the laminate glycoproteins (such as, for example, bone morphogenic protein), glycosaminoglycans (e.g., heparan sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatan sulfate, keratan sulfate, etc.) cellular matrix, and/or other materials. The addition of growth factors may be used to enhance, alter, or modulate proliferation and cell maturation in the cultures. The growth and activity of cells in culture can be affected by a variety of growth factors such as platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-beta) ,insulin, growth hormone, εomatomedinε, colony stimulating factors, erythropoietin, epidermal growth factor, hepatic erythropoietic factor (hepatopoietin) , and liver-cell growth factor. Other factors which regulate proliferation and/or differentiation include εteroidε proεtaglandins, interleukins, vitamins, and naturally-occurring chalones . For example, transdifferentiation of fibroblasts or bone marrow cells can be modulated by steroids so that the fibroblasts or bone marrow is transformed into adipocyteε, instead of chondrocytes.
After disposition of the subεtrate into the chamber formed by the laminate, the laminate iε incubated in an appropriate nutrient medium containing one or more cells capable of growth and/or differentiation under the influence of the substrate. Many commercially available media such as RPMI 1640, Fisher's, Iscove's, McCoy' ε, and the like may be suitable for use. The laminate can be suspended or floated in the medium during the incubation period in order to maximize proliferative and/or differentiation activity. In addition, the culture should be fed periodically to remove the spent media, depopulate released cells, and add fresh media.
A wide variety of cells can be introduced into the laminate, depending upon the particular substrate disposed within the chamber. For example, if DBP is the enclosed substrate, fibroblasts are prepared and added to the laminate. Fibroblasts may be readily isolated by disaggregating an appropriate organ or tissue which is to serve as the source of the fibroblasts. This may be readily accomplished using techniques known to those skilled in the art. For example, the tissue or organ can be disaggregated mechanically and/or treated with digestive enzymes and/or chelating agents that weaken the connections between neighboring cells making it possible to disperse the tissue into a suspension of individual cells without appreciable cell breakage. Enzymatic dissociation can be accomplished by mincing the tissue and treating the minced tissue with any of a number of digestive enzymes either alone or in combination. These include but are not limited to trypsin, chymotrypsin, collagenase, elaεtaεe and/or hyaluronidase, DNaεe, pronase, dispase etc. Mechanical disruption can also be accomplished by a number of methods including, but not limited to the use of grinders, blenderε sieves, homogenizers, pressure cells, or insonators to name but a few. For a review of tissue disaggregation techniques, see
Freεhney, Culture of Animal Cellε, A Manual of Basic Technique, 2d Ed., A.R. Liεε, Inc. New York, 1987, Ch. 9, pp. 107-126.
A unique feature of the preεent invention iε the manner and apparatus used to fabricate the laminated cell culture device of the invention. A mold made of an inert elastomer (i.e. Tygon® tubing) is provided. FIGURE 2 illustrates a preferred mold and laminate in an intermediate step in the manufacturing process. The mold 30 is a substantially annular collar 32 having opposed ends 34, 36. To make the mold, 3/8" Tygon® tubing is cut into approximately 1 cm pieces. One end 36 of the tube is closed off by gluing the tube on a tissue culture dish 31 with, for example. Medical Adhesive Silicon (Dow Corning). The molds are dried.
A preferred laminate is formed by providing a first solution 38 (up to several hundred microliters) of structural protein (i.e. a collagen matrix) to the closed end 36 of mold 30. Between 80-200 microliters of structural protein solution is optimal for the preferred laminate structures of the invention.
The mold is then frozen. A spacer 40 (preferably wet paper) is placed on top of the frozen matrix 38, but the peripheral edges of the matrix remain exposed. The spacer 40 and matrix 38 are again frozen and a second amount of structural protein matrix 42 (up to several hundred microliters) deposited on top of spacer 40. A second spacer 44 is placed over the second structural protein matrix 42. The peripheral edges of the second matrix do not need to remain exposed. The entire mold is lyophilized.
After lyophilization, the spacers are carefully removed from the structural protein matrix. The interior peripheral surfaces of the layers spontaneouεly εeal or otherwiεe anneal together during the lyophilization procedure to form a seam, defining a substantially hollow chamber that is substantially free of the structural matrix material. This seam extends subεtantially around the entire outer periphery of the
laminate (See FIGURE 1). The use of the spacers eliminates development of an impermeable, dense shell of protein that typically forms during lyophilization. Lyophilization provides enough strength to the laminate to allow for ease of handling and packing of the laminate.
After the laminate is formed, the chamber is packed with the substrate. A preferred substrate is demineralized bone powder, prepared from cortical sections of femoral and tibial bones (i.e. rat) (See Example 1). The bone is extracted with an alcohol solvent (i.e. ethanol) and an ether solvent. The dehydrated bone is frozen and pulverized in, for example, a liquid nitrogen impacting mill (Spex Industries, Metuchen, NJ) . Bone pieces are seived and collected, preferably as a fraction between 75 and 250 um. Mineral extraction iε performed with acid (i.e. 0.5 HC1) for several hours at room temperature. Final drying is achieved by solvent washing, as above.
Optionally, the laminate containing the substrate is secured to a support device. The support device is substantially identical to the manufacturing mold with the addition of several features.
Figure 3 illustrates a support 50 after the substrate 22 has been disposed into chamber 20. A plurality of conduits 52 has been cut into one end 54 of 3/8" Tygon tubing. The conduits provide for entry of culture fluid from outside the support. The opposed end 55 of support 50 receives the target cells (not shown) and the space 57 defined by laminate's peripheral surface 16, the inner periphery 60 of the support 50, and end 55, preferably serves as a receptacle for target cells so that they may infiltrate and migrate into the laminate.
A pair of opposed flanges 56, 58 or silicon O-rings is placed on the inner periphery 60 of support 50. The flanges 56,58 are in facing relationship to each other. The opposed flanges on the inner periphery 60 of the support 50 receives the peripheral seam 21 of the laminate. Silicon tubing
(about 3/8" in diameter, 1/16" wall thickness, 1.5mm in length) is preferably used to make the flanges. The silicon tubing is fit in place on the inner periphery 60 of support 50.
The support containing the laminate packed with substrate can be used in the preliminary stages of in vitro cell culture to provide a stable receptacle and platform for the migration, growth, and differentiation of one or more cells. It will be understood that a variety of other laminate configurations can be fabricated using the present methods. For example, a multichamber laminate can be easily fabricated using several spacers and more than two layers of structural matrix material. Each chamber can be charged with the same, or different, substrate.
The device of the invention can be used in a variety of applications. These include, but are not limited to, transplantation or implantation of the laminate in vivo; screening differentiation inducing factors, cytotoxic compounds, allergenε, growth/regulatory factors, pharmaceutical compounds, etc., iji vitro; studying the mechanism by which drugs and/or growth factors operate; and the production of biologically active productε, to name but a few.
For tranεplantation or implantation in vivo into a subject (i.e. an animal, preferably a mammal such as a human) , either the cells obtained from the laminate or the entire laminate could be implanted, depending upon the type of tissue involved. For example, three-dimensional bone cultures can be maintained in vitro for long periods; the cells isolated from theεe cultureε can be uεed in tranεplantation or the entire laminate may be implanted.
Three-dimensional tissue culture implants may, according to the invention, be used to replace or augment existing tissue, to introduce new or altered tissue, to modify artificial prostheses, or to join together biological tissues or structures. For example, and not by way cf limitation.
specific embodiments of the invention would include (i) removal of cells from a subject (i.e. fibroblasts from a human skin biopsy sample), in vitro induction of these cells to form chondroblasts, and production of three-dimensional bone culture implants used vivo in the same subject to replace bone destroyed during chemotherapeutic treatment; (ii) genetically altering cells grown in three-dimensional culture, for example to produce three-dimensional cultures of chondroblasts which express a recombinant gene encoding a therapeutic agent, and their use jn vivo to replace bone destroyed during chemotherapeutic treatment.
The device may be used j vitro to screen a wide variety of putative substrates and growth/regulatory factors. To this end, cell cultures are maintained in vitro and exposed to a particular substrate suspected of having inducing activity. Response of the cell culture is assayed using conventional methods (see, Example 1). The ability of compounds to modulate (i.e. enhance or suppress) inductive activity can also be measured by, for example, vital staining techniques or by analyzing the cellular contents of the laminate e.g., by total cell counts, and differential cell counts. This may be accomplished using standard cytological, biochemical and/or histological techniques, including the use of immunocytochemical techniques employing antibodies that define type-specific cellular antigenε. The effect of variouε drugs on cells cultured in the device may also be assessed. For example, drugs that increase bone and/or cartilage formation can be tested on chondroblaεt cultures.
The device of the invention can also be used to study and asεeεs the biocompatability of various structural matrix materials. Laminates can be fabricated of the material to be tested and the laminate charged with a particular substrate. The effect of different laminate materials on the inductive capacity of the subεtrate can be aεεayed uεing the methodε deεcribed herein.
The device of the invention may be used as a model system for the study of physiologic or pathologic conditions. For example, in a specific embodiment of the invention, a laminate may be used as a model for a bone syεtem can be used to study the penetration of subεtanceε through bone, and/or aε a model system to study the effect of bone tranεdifferentiation factors.
Depending upon the intended use for the proliferated and/or differentiated cellε, variouε specialized cells may be added to the device. For example, the long-term growth of bone cells in the laminate may be enhanced by the addition of certain mononuclear cell populations or by the addition of growth factorε to the culture medium.
The device has utility In vitro to produce biological productε in high yield. For example, a differentiated cell which, in the presence of the substrate, produces large quantities of a particular biological product could be grown using the device and the product can be trapped and isolated within the laminate material (e.g., extracellular matrix, cell-surface-associated products) . Differentiated cells which produce more soluble products (e.g. growth factorε, regulatory factors, peptides, hormones, etc.), can also be grown. In particular, if the transformed cell excretes the product directly into the laminate matrix or the nutrient medium, the product can be isolated from the laminate, into the nutrient medium, the product may be readily isolated from the laminate or medium using standard separation techniques (e.g., HPLC, column chromatography, electrophoretic techniques, to name but a few). A "bioreactor" could be thereforedeviεed which would take advantage of a continuous flow method for feeding the laminate in vitro for the production of, for example, extracellular matrix or cell-surface-associated products of target cells.
A kit for in vitro studies will comprise the laminate of the invention having a εubεtrate diεposed within the chamber, the substrate specific for growing and/or differentiating
cells of interest; cellε of interest seeded on the laminate; and reagents for determining the effects of a given compound on growth and/or differentiation of the cells of interest. Preferably, the laminate iε a collagen matrix and the substrate is DBP.
In another embodiment, the above kit can comprise a collagen laminate lacking subεtrate and cellε. The laminate can be εold freeze-dried or frozen. The kit can compriεe the subεtrate in a separate container for disposition into the chamber of the laminate at an appropriate time. The kit can further comprise one or more reagents for determining the effect of a compound on cells of intereεt.
An Example of the invention is described in the section below. For purposeε of description only, and not by way of limitation, the laminate of the invention is described based upon DBP as substrate and fibroblasts as cells induced by the substrate. It is expressly understood that the device can be used with other types of cells and substrateε.
Example 1: Chondroinduction of Fibroblaεtε MATERIALS AND METHODS
Initial preparation of mold/support material Medical grade Tygon® tubing (mfg. by Norton, Akron, OH) of inner diameter 3/8" and thickness 3/32" is cut into 1cm lengths. The pieces are washed with cell-culture grade soap in a sonicator, then rinsed with tap water and distilled water. The pieces are packaged and autoclaved at 121 degreeε
2
C, 1 kg/cm preεsure for 10 minutes. To form a mold, one εide of the tubing is glued to a 60mm culture dish with medical grade εilicon glue. The mold and dish are dried for 12hr in sterile hood.
Composite demineralized bone/collagen matrices: Type 1 soluble collagen solution, for example, Celiagen® (Cat. # PC-5 -ICN Biomedicals, CA) , was used for the laminate construction. This consists of purified insoluble type 1 collagen extracted from calf dermis that has
been solubilized by pepsin treatment in order to neutralize this collagen solution. About 1/100 of the final volume of 1 M HΞPES [pH 7.4 (final 10 mM) ] and the same volume of 1 M NaHCO_(final 10 mM) were added to the collagen solution. Next, about 120 microliters of 0.5% collagen εolution (ICN Biomedicalε, IL) was poured into the mold and frozen at -20°C. The concentration of collagen can vary since poroεity of the final matrix iε a function of the collagen concentrationε . A 0.5% pepsin-digested collagen solution which is ph 3 in acetic acid is most preferred. The concentration, however, can be greater than 0.5%, although concentrations much less than 0.3% will not yield a strong enough collagen matrix. Next, a wet folded piece of paper was placed on the top surface of the frozen collagen, but allowing a small, uncovered edge of the laminate to remain exposed.
After freezing, an additional 130 microliters of ice-cold collagen solution was poured over the frozen collagen and frozen again. Finally, a wet tissue was placed on the added frozen collagen to avoid the formation of a dense collagen shell over the laminate. After lyophilization, the tisεueε were carefully removed from the collagen. Both sides of the laminate were irradiated by UV light for three hours. Approximately 10 mg of DBP was inεerted between layerε of the collagen laminate and the outer periphery of the layers was εecured to a support with placement of εilicon flanges above and below the peripheral εurfaceε of the laminate (See, for example, FIGURE 3).
Demineralized bone powder (DBP) waε prepared according to standard protocols. Briefly, mammalian bones, for example diaphyseal boneε from cowε, are stripped of muscle and fat, cleaned of periosteum, demarrowed by pressure and cold water, and dried and fragmented by crushing and pulverizing in a large mill. Care is taken to prevent heating by using liquid nitrogen. The pulverized bone is milled to a particle size between about 75-250 microns . The bone powder is then
demineralized with 20 volumes of 0.5N HCl at 4 C for about 24 hours. The acid iε removed every eight hours and fresh acid is added. The powder iε then waεhed with a large volume of water until the waεh εolution has a neutral pH. The demineralized bone powder is further extracted with three volumeε of chloroform and methanol (3:1). The particulate bone iε washed with one volume of absolute ethanol and dehydrated with one volume of anhydrouε ether.
The DBP iε rendered inactive by dissociate extraction with 20 volumes of 4M guanidine-HCl. The solid material iε then waεhed with water, waεhed with one volume of absolute ethanol and dehydrated with one volume of anhydrous ether.
Cell culture: Human dermal fibroblasts were isolated by explant culture in DMEM with 10% FBS and antibiotics. Human costal chondrocytes (used as positive controls) were isolated by collagenase digestion and cultured in Ham's F-12 with 10% FBS and antibiotics. Bovine articular chondrocytes were also used as a positive control. About 1x10° target cells were introduced into the open end of the support and allowed to contact the laminate on its upper peripheral surface. In others, cells were inoculated directly into the laminate. After overnight incubation, the laminates were cultured in the molds in a vertical position for achieving effective nutrient exchange. After 3 days, the laminates were removed from the mold and the laminates only were subsequently incubated. Media were changed twice weekly. On days 7 or 10, laminates were harvested and fixed in 2% paraformaldehyde, as described below.
Analysis : For asseεs ent of in vivo activity, laminates with/without DBP or guanidine-extracted DBP residue were deposited in subcutaneous pockets in 28-day-old rats. Laminates were harvested at intervals, fixed in 2% parafcrmaldehyde, and embedded in giycol methacrylate (JB-4) or paraffin. A series of twentv- icron sections were stained
with toluidine blue, enabling visualization of metachromatic matrix around cellε. The twenty-micron εectionε were blocked with 5% normal goat serum and stained with various amounts (1:100 to 1:1000 dilution) of monoclonal antibodies against chondroitin sulfate: CS-56 (ICN Biomedicals, Cat. # 63-650-1) or D type (MO-225: Seikagaku America, Cat. tt 270802), anti-type II collagen (Chemicon Co., Cat. # MAB1330), keratan sulfate (Seikagaku, Cat. # 270786), anti-proteoglycan (ΔDi-OS: Seikagaku, Cat. 8 270788), ΔDi-6S: Seikagaku, Cat. tt 270789), and ΔDi-4S:Seikagaku, Cat. tt 270790) after chondroitinase ABC digestion. For visualization, the silver-enhanced immunogold procedure was used (AuroProbe LM R, Janssen Biotech NV, Belgium) .
RESULTS
In vivo: At intervals, reactive tissue was harvested for histological analysis. DBP laminates prepared as described were not inflammatory, permitted substantial vascularization, provided a scaffold for cellular migration, and induced endochondral osteogenesis.
In vitro: In samples in which fibroblasts were inoculated into the chamber of the laminate in contact with the DBP εubεtrate, viability waε good until day 7 but, thereafter, degenerative cellε predominated. It is believed that these cellε underwent pO„ changeε during the transfer that rendered them not viable. Best resultε were achieved when fibroblaεtε were seeded on top of the laminate and allowed to migrate through the collagen matrix.
In chondrocyte-bearing laminates, cells infiltrated the collagen network and attached to both DBP and DBP residue. By day 3, metachromatic granular deposits surrounded chondrocytes with immunohistochemical reactivity with cartilage-specific antibodies. In fibroblast-bearing laminates, migration and viability were equivalent with DBP and DBP residue. Fibroblasts were attached to the collagen network and to the particles with evidence of ECM synthesis.
Metachromasia and immunoreactivity with cartilage-specific antibodies were not seen around fibroblasts on the collagen laminate nor on the DBP residue. In contrast, fibroblasts in close approximation with DBP were surrounded by metachromatic, immunoreative matrix, similar to that around bonafide chondrocytes.
Anti-keratan sulfate antibodies showed intense staining in and around human chondrocytes attached to the laminate and between DBP particles. Cartilage-specific antibodies were reactive with human fibroblasts on DBP. Also, antibody to chondroitin-4 sulfate was positive for cellε on DBP and negative for cellε on guanidine-extracted DBP or collagen alone.
CONCLUSIONS
Human dermal fibroblaεtε expressed chondrocytic properties when cultured in DBP/collagen laminates of the invention. This 3-dimensional in vitro system optimized cellular infiltration. Cells within the laminates were viable for at least 2 weeks. Packing geometry for DBP more closely mimicked the in vivo microenvironment. Cartilage-like matrix was synthesized by dermal fibroblasts near DBP. This system will valuable to define 1) the cell biology of transdifferentiation by osteoinductive material, 2) the influence of other extracellular components (e.g. hyaluronic acid) and soluble factors (e.g. PDGF, TGF-beta) on differentiation, 3) an in vitro biassay of other inductive factors, and 4) the development of composite substitutes for εkeletal reconεtruction.
EQUIVALENTS
While εpecific designε have been εhown in the preferred embodiments, the invention is not intended to limited by these specific designε. It should be underεtood that the foregoing description of the invention is intended merely to be illustrative and other embodiments, modifications and
equivalents thereof may be apparent to those skilled in the art without departing from the scope or spirit of the invention.
Claims
1. A cell induction device comprising: a laminate including first and second layers of a permeable structural matrix, each of said layerε having an exterior and interior peripheral surface, said interior peripheral εurfaceε of εaid firεt and second layerε engaged together in facing relationship, defining a substantially hollow chamber therebetween that lacks said structural matrix
2. The device of claim 1, further comprising a subεtrate disposed within said chamber, the substrate having inducing activity towards one or more cells that come in contact with said laminate.
3. The device of claim 1, wherein said chamber is constructed and arranged to optimize packing density of the substrate.
4. The device of claim l, wherein said engaged interior peripheral surfaces define a seam extending around an outer periphery of said laminate.
5. The device of claim l, wherein εaid laminate iε biocompatible with respect to said substrate.
6. The device of claims 1 or 2, further comprising a support engaged with said exterior peripheral surfaces of said laminate.
7. The device of claim 6, wherein said support iε engaged with εaid outer peripheral seam.
8. The device of claim 7, wherein εaid support co priseε an annular collar having opposed endε, εaid peripheral εea of εaid laminate εupported on an inner perinheral εurface of εaid collar.
9. The device of claim 8, wherein said laminate is disposed intermediate said opposed ends of said collar.
10. The device of claim 9, wherein one of said opposed ends, said inner peripheral surface of said collar, and an exterior peripheral surface of said laminate, define a receptacle for receiving one or more cells capable of being induced by said subεtrate.
11. The device of claim 8, wherein said inner peripheral surface has defined therein a slit, said slit engaged with said outer peripheral surfaces of εaid laminate.
12. The device of claim 11, wherein εaid slit is defined by a pair of flanges in facing relationship, said flanges supported on said inner peripheral surface of said collar, and wherein said outer peripheral seam of said laminate is engaged between said pair of flanges.
13. The device of claim 8, wherein one of said opposed ends has a plurality of conduits defined therein.
14. The device of claim 13, wherein said conduits are disposed adjacent said end of said collar.
15. The device of claim 1, wherein said structural matrix comprises a structural protein matrix.
16. The device of claim 15, wherein said substrate comprises an osteogenic material.
17. The device of claim 16, wherein said oεteogenic material comprises demineralized bone powder.
18. The device of claim 15, wherein said structural protein comprises collagen.
19. A method for analyzing growth and differentiation of cellε comprising: providing a laminate including first and second layers of structural protein matrix, each of said layers having an exterior and an interior peripheral surface, said interior peripheral surfaces of said first and second layers engaged in facing relationship, defining a subεtantially hollow chamber therebetween, said chamber free of structural protein matrix; disposing a substrate within said chamber, said subεtrate having inducing ability towardε one or more cells; allowing said substrate to contact εaid one or more cells; incubating said laminate in the presence of said cellε for a time sufficient for said cells be induced by said substrate.
20. The method of claim 19, further comprising adding at least one cell growth factor to εaid laminate.
21. The method of claim 20, wherein said cell growth factor added to εaid laminate is selected from the group consisting of bone morphogenic protein, platelet-derived growth factor, and transforming growth factor-beta.
22. The method of claim 19, further comprising adding at least one proteoglycan or glycosoaminoglycan to said laminate.
23. The method of claim 22, wherein said glycosoaminoglycan is selected from the group consisting of chondroitin εulfate, keratan sulfate, heparan εulfate, and hyaluronic acid, and combinationε thereof.
24. The culture device of claim 1, produced by: providing a firεt amount of εtructural matrix material; diεpoεing a firεt spacer on said structural matrix material; providing a second amount of structural matrix material to said firεt spacer; disposing a second spacer on said second amount of εtructural matrix material; lyophilizing said spacers and structural matrix material; and removing εaid spacers from said lyophilized matrix to produce a laminate having interior surfaceε engaged together in facing relationship to define a substantially hollow chamber that is substantially free of the structural matrix material.
25. The culture device of claim 24, wherein said firεt and second amounts of structural matrix material are provided into a mold comprising a tube having opposed ends.
26. The culture device of claim 2, produced by: providing a first amount of structural matrix material; disposing a first spacer on εaid structural matrix material; providing a second amount of structural matrix material to said firεt spacer; disposing a second spacer on said second amount of structural matrix material; lyophilizing said spacers and structural matrix material; removing said spacerε from εaid lyophilized matrix to produce a laminate having interior surfaces engaged together in facing relationship to define a substantially hollow chamber that is substantially free of the structural matrix material; and disposing a subεtrate into said chamber.
27. The culture device of claim 26, wherein said substrate is demineralized bone powder and said structural matrix material comprises collagen.
28. A method of forming a 3-dimensional culture device, comprising the steps of: providing a mold compriεing a tube having opposed ends; depositing a first amount of structural matrix material into said tube; disposing a first spacer on said structural matrix material; depositing a εecond amount of structural matrix material on said first spacer; disposing a second spacer on said second amount of structural matrix material; lyophilizing said mold including said spacers and structural matrix material; and removing εaid spacers from said lyophilized matrix to produce a laminate including first and second layers, each of the layers having exterior and interior peripheral surfaces in which said respective interior peripheral surfaces are engaged together in facing relationship to define a substantially hollow chamber that is substantially free of the structural matrix material.
29. The method of claim 28, further comprising disposing a substrate into said chamber.
30. A device for inducing cell differentiation comprising: wall means, said wall means having an interior surface and an exterior surface, said interior surface defining a chamber, said exterior surface for being placed in contact with biological tissues, said wall means having opening means in communication with said chamber for receiving an induction material and for closing said chamber to contain εaid induction material, εaid wall means comprising a biologically compatible, permeable material capable of receiving cells capable of differentiation, said device for containing an induction material in a biological environment, receiving cells in said chamber and allowing εaid cells to differentiate in the presence of said induction material.
31. The device of claim 30 wherein said wall means and opening means comprise a firεt wall section and a second wall section, said first wall section having a chamber area for receiving an induction material and a peripheral edge area, said second wall section having a cooperating peripheral edge area capable of being received by said peripheral edge area of said first wall section to form said chamber.
32. The device of claim 31 further comprising a support engaging the peripheral edge areas of said first and second wall sections to provide closure of said peripheral edge areas and to facilitate handling.
33. The device of claim 31 wherein said support comprises a housing, said housing having an inner surface and an outer surface, said inner surface defining a cavity and having wall retaining means for engaging said wall means.
34. The device of claim 33 wherein said wall retaining means comprises a groove in the inner surface of said housing, said groove engaging the peripheral edge areas of said first and second wall section.
35. The device of claim 34 wherein said inner surface has two cooperating flanges projecting inwardly in spaced relationship to define said groove.
36. The device of claim 33 wherein said houεing haε two ends, at least one of said ends having planar edge to allow said housing to stably rest on flat surfaces.
37. The device of claim 33 wherein said housing has conduits extending from said outer surface to said inner surface to allow εaid cavity to be in fluid communication with the environment at εaid outer surface when said housing is resting on εaid planar edge.
38. A device for inducing cell differentiation comprising a) wall means, said wall means having an interior surface and an exterior surface, said interior surface defining a chamber, said exterior surface for being placed in contact with a biological tissues, said wall means comprising a biologically compatible permeable material capable of receiving cells capable of differentiating to allow such cells to enter said chamber; and, b) induction material, said induction material capable of causing a cell to differentiate, said induction material contained in said chamber to allow said device to be placed with biological tissue to make cells of an induced type.
39. The device of claim 38 further comprising at least one cell capable of being induced or having been induced by said induction material.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU61379/94A AU6137994A (en) | 1993-02-12 | 1994-02-10 | Cell induction device |
JP6518373A JPH08506506A (en) | 1993-02-12 | 1994-02-10 | Cell guidance device |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/017,281 US5656492A (en) | 1993-02-12 | 1993-02-12 | Cell induction device |
US08/017,281 | 1993-02-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994018307A1 true WO1994018307A1 (en) | 1994-08-18 |
Family
ID=21781737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/001561 WO1994018307A1 (en) | 1993-02-12 | 1994-02-10 | Cell induction device |
Country Status (4)
Country | Link |
---|---|
US (1) | US5656492A (en) |
JP (1) | JPH08506506A (en) |
AU (1) | AU6137994A (en) |
WO (1) | WO1994018307A1 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018583A1 (en) * | 1994-01-11 | 1995-07-13 | Baxter International Inc. | Ported tissue implant systems and methods of using same |
WO1996032076A1 (en) * | 1995-04-11 | 1996-10-17 | Baxter Internatonal Inc. | Tissue implant systems |
WO1996036296A1 (en) * | 1995-05-19 | 1996-11-21 | Baxter International Inc. | Multiple layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue |
DE19540487A1 (en) * | 1995-10-20 | 1997-04-24 | Olaf Schultz | Cell interaction system for induction of artificial 3-dimensional tissue |
EP2125056A1 (en) * | 2007-02-19 | 2009-12-02 | Ticapex AB | Implant assembly |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE250666T1 (en) * | 1996-06-04 | 2003-10-15 | Sulzer Orthopedics Ltd | METHOD FOR PRODUCING CARTILAGE TISSUE AND IMPLANTS |
ATE220564T1 (en) | 1997-08-14 | 2002-08-15 | Sulzer Innotec Ag | COMPOSITION AND DEVICE FOR REPAIRING CARTILAGE TISSUE IN VIVO CONSISTING OF NANOCAPSULES WITH OSTEOINDUCTIVE AND/OR CHONDROINDUCTIVE FACTORS |
DE19911326A1 (en) * | 1999-03-15 | 2000-09-28 | Fege Wolfgang | Device for growing human or animal tissue |
US6447517B1 (en) | 1999-07-23 | 2002-09-10 | Ethicon, Inc. | Instrument for inserting graft fixation device |
US6179840B1 (en) | 1999-07-23 | 2001-01-30 | Ethicon, Inc. | Graft fixation device and method |
US6364884B1 (en) | 1999-07-23 | 2002-04-02 | Ethicon, Inc. | Method of securing a graft using a graft fixation device |
US6402766B2 (en) | 1999-07-23 | 2002-06-11 | Ethicon, Inc. | Graft fixation device combination |
US7214232B2 (en) * | 1999-07-23 | 2007-05-08 | Ethicon, Inc. | Graft fixation device |
US6423073B2 (en) | 1999-07-23 | 2002-07-23 | Ethicon, Inc. | Instrument for inserting graft fixation device |
US6436110B2 (en) | 1999-07-23 | 2002-08-20 | Ethicon, Inc. | Method of securing a graft using a graft fixation device |
US20020095157A1 (en) | 1999-07-23 | 2002-07-18 | Bowman Steven M. | Graft fixation device combination |
US6497707B1 (en) | 1999-07-23 | 2002-12-24 | Ethicon, Inc. | Graft fixation device combination |
JP3865354B2 (en) | 2000-03-02 | 2007-01-10 | 高木産業株式会社 | Cell or tissue culture method |
DE10032808A1 (en) * | 2000-06-30 | 2002-01-17 | Tom Witascheck | Bioreactor growing tissue or complete organ implants by assembly of differing cell types in specific forms and patterns, includes chambers with cavities of differing shape |
CA2365376C (en) | 2000-12-21 | 2006-03-28 | Ethicon, Inc. | Use of reinforced foam implants with enhanced integrity for soft tissue repair and regeneration |
WO2002071927A2 (en) * | 2001-03-12 | 2002-09-19 | The Brigham And Women's Hospital, Inc. | Diagnosis and treatment of skeletal degeneration conditions |
US20040151705A1 (en) | 2002-03-22 | 2004-08-05 | Shuichi Mizuno | Neo-cartilage constructs and a method for preparation thereof |
WO2002076285A2 (en) | 2001-03-23 | 2002-10-03 | Histogenics Corporation | Composition and methods fro the production of biological tissues and tissue constructs |
JP4180509B2 (en) | 2001-07-26 | 2008-11-12 | ウイルソンークック メディカル インク. | Vessel occlusion member and distribution device thereof |
US7622562B2 (en) | 2002-06-26 | 2009-11-24 | Zimmer Orthobiologics, Inc. | Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue |
US7824701B2 (en) | 2002-10-18 | 2010-11-02 | Ethicon, Inc. | Biocompatible scaffold for ligament or tendon repair |
US20040078090A1 (en) | 2002-10-18 | 2004-04-22 | Francois Binette | Biocompatible scaffolds with tissue fragments |
US8197837B2 (en) | 2003-03-07 | 2012-06-12 | Depuy Mitek, Inc. | Method of preparation of bioabsorbable porous reinforced tissue implants and implants thereof |
DE10326746B4 (en) * | 2003-06-13 | 2006-04-06 | Gerlach, Jörg, Dr.med. | Bioreactor in the form of organ copy, process for its preparation and its use for the cultivation, differentiation, preservation and / or use of cells |
US8226715B2 (en) | 2003-06-30 | 2012-07-24 | Depuy Mitek, Inc. | Scaffold for connective tissue repair |
US10583220B2 (en) | 2003-08-11 | 2020-03-10 | DePuy Synthes Products, Inc. | Method and apparatus for resurfacing an articular surface |
US7217294B2 (en) | 2003-08-20 | 2007-05-15 | Histogenics Corp. | Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and method for use thereof |
US7316822B2 (en) | 2003-11-26 | 2008-01-08 | Ethicon, Inc. | Conformable tissue repair implant capable of injection delivery |
US7901461B2 (en) | 2003-12-05 | 2011-03-08 | Ethicon, Inc. | Viable tissue repair implants and methods of use |
US11395865B2 (en) * | 2004-02-09 | 2022-07-26 | DePuy Synthes Products, Inc. | Scaffolds with viable tissue |
US8221780B2 (en) | 2004-04-20 | 2012-07-17 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US8137686B2 (en) | 2004-04-20 | 2012-03-20 | Depuy Mitek, Inc. | Nonwoven tissue scaffold |
US20060110422A1 (en) * | 2004-11-19 | 2006-05-25 | Tas Ahmet C | Conversion of calcite powders into macro- and microporous calcium phosphate scaffolds for medical applications |
WO2007035778A2 (en) | 2005-09-19 | 2007-03-29 | Histogenics Corporation | Cell-support matrix and a method for preparation thereof |
US7833270B2 (en) * | 2006-05-05 | 2010-11-16 | Warsaw Orthopedic, Inc | Implant depots to deliver growth factors to treat osteoporotic bone |
US8753391B2 (en) * | 2007-02-12 | 2014-06-17 | The Trustees Of Columbia University In The City Of New York | Fully synthetic implantable multi-phased scaffold |
US9421304B2 (en) | 2007-07-03 | 2016-08-23 | Histogenics Corporation | Method for improvement of differentiation of mesenchymal stem cells using a double-structured tissue implant |
US8685107B2 (en) | 2007-07-03 | 2014-04-01 | Histogenics Corporation | Double-structured tissue implant and a method for preparation and use thereof |
US20090054984A1 (en) | 2007-08-20 | 2009-02-26 | Histogenics Corporation | Method For Use Of A Double-Structured Tissue Implant For Treatment Of Tissue Defects |
DE102010064098B4 (en) * | 2010-12-23 | 2014-02-13 | Hochschule Wismar | cell reactor |
US9447169B2 (en) * | 2011-03-04 | 2016-09-20 | Orthovita, Inc. | Flowable collagen-based hemostat and methods of use |
US20140148839A1 (en) * | 2012-11-27 | 2014-05-29 | Dusan Pavcnik | Bodily Lumen Closure Apparatus and Method |
US10077420B2 (en) | 2014-12-02 | 2018-09-18 | Histogenics Corporation | Cell and tissue culture container |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2054446A1 (en) * | 1970-11-05 | 1972-05-10 | Henning, George Ernest von, 6800 Mannheim | Biological reaction chamber |
WO1990005179A1 (en) * | 1988-11-02 | 1990-05-17 | E.I. Du Pont De Nemours And Company | Dot matrix membrane cell expansion and maintenance vessel |
EP0403650A1 (en) * | 1988-03-09 | 1990-12-27 | Terumo Kabushiki Kaisha | Medical material permitting cells to enter thereinto and artificial skin |
WO1991001720A1 (en) * | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
EP0421211A1 (en) * | 1989-09-29 | 1991-04-10 | Anawa München Aktiengesellschaft Biologische Laboratorien | Reactor for carrying out biological processes in-vitro, method for carrying out biological processes in-vitro and use of the reactor and method |
EP0531631A1 (en) * | 1991-06-19 | 1993-03-17 | Endotronics, Inc. | Cell culture apparatus |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2189273A (en) * | 1938-06-29 | 1940-02-06 | Wesley P Shomaker | Envelope |
IT1096845B (en) * | 1978-06-30 | 1985-08-26 | Safilo Spa | PROCEDURE FOR THE PRODUCTION OF THERMOSETTING RESIN MANUFACTURES |
GB2075323B (en) * | 1980-03-25 | 1983-08-10 | Greenterior Co Ltd | Soil-less plant growing device |
US4565784A (en) * | 1981-01-26 | 1986-01-21 | Trustees Of Boston University | Hydrogels capable of supporting cell growth |
US4495288A (en) * | 1981-03-13 | 1985-01-22 | Damon Biotech, Inc. | Method of culturing anchorage dependent cells |
US4440750A (en) * | 1982-02-12 | 1984-04-03 | Collagen Corporation | Osteogenic composition and method |
US4485096A (en) * | 1982-02-26 | 1984-11-27 | Massachusetts Institute Of Technology | Tissue-equivalent and method for preparation thereof |
US4559299A (en) * | 1983-02-04 | 1985-12-17 | Brown University Research Foundation Inc. | Cytotoxicity assays in cell culturing devices |
JPS59164723A (en) * | 1983-03-10 | 1984-09-17 | Koken:Kk | Substrate containing regenerated collagen fibril and its preparation |
US4546083A (en) * | 1983-04-22 | 1985-10-08 | Stolle Research & Development Corporation | Method and device for cell culture growth |
US4601893A (en) * | 1984-02-08 | 1986-07-22 | Pfizer Inc. | Laminate device for controlled and prolonged release of substances to an ambient environment and method of use |
US5032508A (en) * | 1988-09-08 | 1991-07-16 | Marrow-Tech, Inc. | Three-dimensional cell and tissue culture system |
US4835102A (en) * | 1987-03-31 | 1989-05-30 | Eugene Bell | Tissue equivalent test systems |
US5015584A (en) * | 1987-10-14 | 1991-05-14 | Board Of Regents, The University Of Texas System | Epidermal graft system |
US5108753A (en) * | 1988-04-08 | 1992-04-28 | Creative Biomolecules | Osteogenic devices |
US5024841A (en) * | 1988-06-30 | 1991-06-18 | Collagen Corporation | Collagen wound healing matrices and process for their production |
US4996154A (en) * | 1989-05-04 | 1991-02-26 | Millipore Corporation | Method for growing cellular tissue |
-
1993
- 1993-02-12 US US08/017,281 patent/US5656492A/en not_active Expired - Fee Related
-
1994
- 1994-02-10 WO PCT/US1994/001561 patent/WO1994018307A1/en active Application Filing
- 1994-02-10 AU AU61379/94A patent/AU6137994A/en not_active Abandoned
- 1994-02-10 JP JP6518373A patent/JPH08506506A/en not_active Ceased
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2054446A1 (en) * | 1970-11-05 | 1972-05-10 | Henning, George Ernest von, 6800 Mannheim | Biological reaction chamber |
EP0403650A1 (en) * | 1988-03-09 | 1990-12-27 | Terumo Kabushiki Kaisha | Medical material permitting cells to enter thereinto and artificial skin |
WO1990005179A1 (en) * | 1988-11-02 | 1990-05-17 | E.I. Du Pont De Nemours And Company | Dot matrix membrane cell expansion and maintenance vessel |
WO1991001720A1 (en) * | 1989-08-07 | 1991-02-21 | Herman Wade Schlameus | Composition and method of promoting hard tissue healing |
EP0421211A1 (en) * | 1989-09-29 | 1991-04-10 | Anawa München Aktiengesellschaft Biologische Laboratorien | Reactor for carrying out biological processes in-vitro, method for carrying out biological processes in-vitro and use of the reactor and method |
EP0531631A1 (en) * | 1991-06-19 | 1993-03-17 | Endotronics, Inc. | Cell culture apparatus |
Non-Patent Citations (1)
Title |
---|
MIZUNO ET AL: "A COLLAGEN/DBP SPONGE SYSTEM DESIGNED FOR IN VITRO ANALYSIS OF CHONDROINDUCTION", MATERIALS RESEARCH SOCIETY SYMPOSIUM PROCEEDINGS.TISSUE-INDUCING BIOMATERIALS, vol. 252, 4 December 1991 (1991-12-04), BOSTON,MASSACHUSETTS,USA * |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995018583A1 (en) * | 1994-01-11 | 1995-07-13 | Baxter International Inc. | Ported tissue implant systems and methods of using same |
WO1996032076A1 (en) * | 1995-04-11 | 1996-10-17 | Baxter Internatonal Inc. | Tissue implant systems |
WO1996036296A1 (en) * | 1995-05-19 | 1996-11-21 | Baxter International Inc. | Multiple layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue |
US6060640A (en) * | 1995-05-19 | 2000-05-09 | Baxter International Inc. | Multiple-layer, formed-in-place immunoisolation membrane structures for implantation of cells in host tissue |
DE19540487A1 (en) * | 1995-10-20 | 1997-04-24 | Olaf Schultz | Cell interaction system for induction of artificial 3-dimensional tissue |
EP2125056A1 (en) * | 2007-02-19 | 2009-12-02 | Ticapex AB | Implant assembly |
EP2125056A4 (en) * | 2007-02-19 | 2014-09-24 | Ticapex Ab | Implant assembly |
Also Published As
Publication number | Publication date |
---|---|
JPH08506506A (en) | 1996-07-16 |
US5656492A (en) | 1997-08-12 |
AU6137994A (en) | 1994-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5656492A (en) | Cell induction device | |
Ferrera et al. | Three-dimensional cultures of normal human osteoblasts: proliferation and differentiation potential in vitro and upon ectopic implantation in nude mice | |
AU719160B2 (en) | Submucosa as a growth substrate for cells | |
CN101589139B (en) | Artificial cartilage containing chondrocytes obtained from costal cartilage and preparation process thereof | |
Rotter et al. | Cartilage reconstruction in head and neck surgery: comparison of resorbable polymer scaffolds for tissue engineering of human septal cartilage | |
KR100979664B1 (en) | Adipose-derived stem cells and lattices | |
AU689605B2 (en) | Three-dimensional cartilage cultures | |
Mizuno et al. | Chondroinduction of human dermal fibroblasts by demineralized bone in three-dimensional culture | |
KR19990022216A (en) | Naturally Secreted Extracellular Matrix Compositions and Methods | |
Menard et al. | Contractile behavior of smooth muscle actin-containing osteoblasts in collagen-GAG matrices in vitro: implant-related cell contraction | |
Sohier et al. | Hydrogel/calcium phosphate composites require specific properties for three-dimensional culture of human bone mesenchymal cells | |
CA2410944A1 (en) | Cartilage replacement and method for its production | |
Song et al. | Fabrication and development of artificial osteochondral constructs based on cancellous bone/hydrogel hybrid scaffold | |
Hartman et al. | Ectopic bone formation in rats: the importance of vascularity of the acceptor site | |
Voytik-Harbin | Three-dimensional extracellular matrix substrates for cell culture | |
US11786636B2 (en) | Methods for complex tissue engineering | |
AU2002364653A1 (en) | Cell constructs cultured in vitro, preparation and uses | |
Riccio et al. | Cultures of human embryonic osteoblasts: a new in vitro model for biocompatibility studies | |
Cheung | In vitro cartilage formation on porous hydroxyapatite ceramic granules | |
Zhao et al. | In vitro study of bioactivity of homemade tissue-engineered periosteum | |
Tang et al. | Osteogenesis of freeze-dried cancellous bone allograft loaded with autologous marrow-derived mesenchymal cells | |
JP2021505344A (en) | Compositions and Methods for Repairing Cartilage Defects | |
Glowacki et al. | Induced chondroblastic differentiation of human fibroblasts by three-dimensional culture with demineralized bone matrix | |
CN115516080A (en) | Decellularized organ tissue-derived scaffold for culturing and transplanting organ organoids and method for manufacturing same | |
Sikavitsas et al. | Fluid flow increases mineralized matrix deposition in three-dimensional perfusion culture of marrow stromal osteoblasts in a dose-dependent manner |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU BB BG BR BY CA CN CZ FI HU JP KP KR KZ LK LV MG MN MW NO NZ PL RO RU SD SK UA UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |